Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 96

1.

Modeling Human Prostate Cancer Progression in vitro.

Liu TT, Ewald JA, Ricke EA, Bell R, Collins C, Ricke WA.

Carcinogenesis. 2018 Dec 22. doi: 10.1093/carcin/bgy185. [Epub ahead of print]

PMID:
30590461
2.

TMPRSS2- driven ERG expression in vivo increases self-renewal and maintains expression in a castration resistant subpopulation.

Casey OM, Fang L, Hynes PG, Abou-Kheir WG, Martin PL, Tillman HS, Petrovics G, Awwad HO, Ward Y, Lake R, Zhang L, Kelly K.

PLoS One. 2012;7(7):e41668. doi: 10.1371/journal.pone.0041668. Epub 2012 Jul 30.

3.

Quantitative expression of TMPRSS2 transcript in prostate tumor cells reflects TMPRSS2-ERG fusion status.

Mwamukonda K, Chen Y, Ravindranath L, Furusato B, Hu Y, Sterbis J, Osborn D, Rosner I, Sesterhenn IA, McLeod DG, Srivastava S, Petrovics G.

Prostate Cancer Prostatic Dis. 2010 Mar;13(1):47-51. doi: 10.1038/pcan.2009.28. Epub 2009 Jul 14.

4.

Relation of ETS transcription factor family member ERG, androgen receptor and topoisomerase 2β expression to TMPRSS2-ERG fusion status in prostate cancer.

Kolar Z, Burdova A, Jamaspishvili T, Bouchal J, Kucerova R, Bienova M, Kral M, Student V.

Neoplasma. 2014;61(1):9-16.

PMID:
24195515
5.

Genetic interaction between Tmprss2-ERG gene fusion and Nkx3.1-loss does not enhance prostate tumorigenesis in mouse models.

Linn DE, Bronson RT, Li Z.

PLoS One. 2015 Mar 17;10(3):e0120628. doi: 10.1371/journal.pone.0120628. eCollection 2015.

6.

DNA damage signalling barrier, oxidative stress and treatment-relevant DNA repair factor alterations during progression of human prostate cancer.

Kurfurstova D, Bartkova J, Vrtel R, Mickova A, Burdova A, Majera D, Mistrik M, Kral M, Santer FR, Bouchal J, Bartek J.

Mol Oncol. 2016 Jun;10(6):879-94. doi: 10.1016/j.molonc.2016.02.005. Epub 2016 Mar 3.

7.

Androgen deprivation induces selective outgrowth of aggressive hormone-refractory prostate cancer clones expressing distinct cellular and molecular properties not present in parental androgen-dependent cancer cells.

Tso CL, McBride WH, Sun J, Patel B, Tsui KH, Paik SH, Gitlitz B, Caliliw R, van Ophoven A, Wu L, deKernion J, Belldegrun A.

Cancer J. 2000 Jul-Aug;6(4):220-33.

PMID:
11038142
8.

TMPRSS2:ERG gene fusion expression regulates bone markers and enhances the osteoblastic phenotype of prostate cancer bone metastases.

Delliaux C, Tian TV, Bouchet M, Fradet A, Vanpouille N, Flourens A, Deplus R, Villers A, Leroy X, Clézardin P, de Launoit Y, Bonnelye E, Duterque-Coquillaud M.

Cancer Lett. 2018 Dec 1;438:32-43. doi: 10.1016/j.canlet.2018.08.027. Epub 2018 Sep 7.

PMID:
30201302
9.

Protocols for Studies on TMPRSS2/ERG in Prostate Cancer.

Pakula H, Linn DE, Schmidt DR, Van Gorsel M, Vander Heiden MG, Li Z.

Methods Mol Biol. 2018;1786:131-151. doi: 10.1007/978-1-4939-7845-8_8.

PMID:
29786791
10.

Low Frequency of the ERG Oncogene Alterations in Prostate Cancer Patients from India.

Rawal S, Young D, Williams M, Colombo M, Krishnappa R, Petrovics G, McLeod DG, Srivastava S, Sesterhenn IA.

J Cancer. 2013 Jul 5;4(6):468-72. doi: 10.7150/jca.6568. Print 2013.

11.

Functional antagonism of TMPRSS2-ERG splice variants in prostate cancer.

Rastogi A, Tan SH, Mohamed AA, Chen Y, Hu Y, Petrovics G, Sreenath T, Kagan J, Srivastava S, McLeod DG, Sesterhenn IA, Srivastava S, Dobi A, Srinivasan A.

Genes Cancer. 2014 Jul;5(7-8):273-84.

12.

TMPRSS2-ERG fusion, a common genomic alteration in prostate cancer activates C-MYC and abrogates prostate epithelial differentiation.

Sun C, Dobi A, Mohamed A, Li H, Thangapazham RL, Furusato B, Shaheduzzaman S, Tan SH, Vaidyanathan G, Whitman E, Hawksworth DJ, Chen Y, Nau M, Patel V, Vahey M, Gutkind JS, Sreenath T, Petrovics G, Sesterhenn IA, McLeod DG, Srivastava S.

Oncogene. 2008 Sep 11;27(40):5348-53. doi: 10.1038/onc.2008.183. Epub 2008 Jun 9.

PMID:
18542058
13.

Prostate cancer tissues with positive TMPRSS2-ERG-gene-fusion status may display enhanced nerve density.

Hänze J, Rexin P, Jakubowski P, Schreiber H, Heers H, Lingelbach S, Kinscherf R, Weihe E, Hofmann R, Hegele A.

Urol Oncol. 2018 Sep 18. pii: S1078-1439(18)30292-8. doi: 10.1016/j.urolonc.2018.07.019. [Epub ahead of print] Review.

PMID:
30241953
14.

Minimum altered regions in early prostate cancer progression identified by high resolution whole genome tiling path BAC array comparative hybridization.

Watson SK, Woolcock BW, Fee JN, Bainbridge TC, Webber D, Kinahan TJ, Lam WL, Vielkind JR.

Prostate. 2009 Jun 15;69(9):961-75. doi: 10.1002/pros.20949.

PMID:
19267368
15.

Antibody-independent targeted quantification of TMPRSS2-ERG fusion protein products in prostate cancer.

He J, Sun X, Shi T, Schepmoes AA, Fillmore TL, Petyuk VA, Xie F, Zhao R, Gritsenko MA, Yang F, Kitabayashi N, Chae SS, Rubin MA, Siddiqui J, Wei JT, Chinnaiyan AM, Qian WJ, Smith RD, Kagan J, Srivastava S, Rodland KD, Liu T, Camp DG 2nd.

Mol Oncol. 2014 Oct;8(7):1169-80. doi: 10.1016/j.molonc.2014.02.004. Epub 2014 Feb 21.

16.

Overexpression of prostate-specific TMPRSS2(exon 0)-ERG fusion transcripts corresponds with favorable prognosis of prostate cancer.

Hermans KG, Boormans JL, Gasi D, van Leenders GJ, Jenster G, Verhagen PC, Trapman J.

Clin Cancer Res. 2009 Oct 15;15(20):6398-403. doi: 10.1158/1078-0432.CCR-09-1176. Epub 2009 Oct 13.

17.

Significance of the TMPRSS2:ERG gene fusion in prostate cancer.

Wang Z, Wang Y, Zhang J, Hu Q, Zhi F, Zhang S, Mao D, Zhang Y, Liang H.

Mol Med Rep. 2017 Oct;16(4):5450-5458. doi: 10.3892/mmr.2017.7281. Epub 2017 Aug 18.

18.

TMPRSS2-ERG -specific transcriptional modulation is associated with prostate cancer biomarkers and TGF-β signaling.

Brase JC, Johannes M, Mannsperger H, Fälth M, Metzger J, Kacprzyk LA, Andrasiuk T, Gade S, Meister M, Sirma H, Sauter G, Simon R, Schlomm T, Beissbarth T, Korf U, Kuner R, Sültmann H.

BMC Cancer. 2011 Dec 5;11:507. doi: 10.1186/1471-2407-11-507.

19.

Clinical implications of TMPRSS2-ERG gene fusion expression in patients with prostate cancer treated with radical prostatectomy.

Rubio-Briones J, Fernández-Serra A, Calatrava A, García-Casado Z, Rubio L, Bonillo MA, Iborra I, Solsona E, López-Guerrero JA.

J Urol. 2010 May;183(5):2054-61. doi: 10.1016/j.juro.2009.12.096. Epub 2010 Mar 19.

PMID:
20303538
20.

Detection of TMPRSS2-ERG fusion gene expression in prostate cancer specimens by a novel assay using branched DNA.

Lu B, Maqsodi B, Yang W, McMaster GK, Perner S, Regan M, Bubley GJ, Balk SP, Rubin M, Sanda MG.

Urology. 2009 Nov;74(5):1156-61. doi: 10.1016/j.urology.2009.01.087. Epub 2009 Aug 3.

Supplemental Content

Support Center